Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Regenxbio (RGNX) stock in plain English

Free brief · no signupStart here
RGNXPublished Nov 19, 2026
Regenxbio Inc
Healthcare · Biotechnology
Develops gene therapy candidates for retinal, neuromuscular, and metabolic diseases.
Assets:
NAV delivery platformProprietary virus technology used in therapies like Zolgensma
Rockville campusMaryland headquarters housing internal manufacturing and laboratory space
Late-stage pipelineOngoing pivotal clinical trials for eye and rare metabolic conditions
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

40
OPS ScoreOperating finances
Latest quote
-1.10%$7.18
$474.76M
n/a (loss)
$154.14M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was RGNX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Regenxbio (RGNX) do?

Regenxbio Inc (RGNX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops gene therapy candidates for retinal, neuromuscular, and metabolic diseases. It develops gene therapies and licenses its proprietary virus delivery system to outside pharmaceutical firms. It is worth $474.76M on the market and sold $154.14M over the last year.

Market cap
$474.76M
P/E ratio
None (reported a loss)
Annual sales
$154.14M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

RGNX’s flags, in plain English

Each flag is a number from Regenxbio’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 4.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 77.8% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Insiders Hold

Insiders own 7.5% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Debt Is Driving

Heavy debt, 170% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about RGNX

How big is Regenxbio?

Regenxbio’s market cap is $474.76M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $154.14M: what customers paid the company over the last year, before any costs.

What is RGNX’s P/E ratio?

RGNX has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with RGNX?

The company depends heavily on royalty payments from Novartis for sales of Zolgensma. That is one risk on Regenxbio’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Regenxbio’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RGNX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card